Saturday, April 06, 2024 8:37:14 PM
As I understand it, the 120 day goal replaces the 150 days, it's not added to it.
All these goals are simply targets the regulators are striving to. Our FDA normally shoots for 6 months in setting their PDUFA date for anything worthy of priority review, and that certainly includes all deadly diseases, like cancer. All the regulators can delay without denying, but I believe we're in a good position to get the UK decision on time, or early.
I forget who appeared to have relationships with the UK regulators, but I believed the indication that now RFI was generated in the initial review period, so I believe that we're on track for a very rapid approval.
The only approvals I've been involved with never had the sponsor say anything about discussions with the regulator from the time they filed until they received something official from the regulator. If it wasn't an approval, they announced what was being required, in some cases it was data they could get that wouldn't cause a major delay, in others it was additional trials, and substantial delay. In every case that I believed a product should be approved, it was, but in some case it was after a multi-year delay for the new trials.
Gary
All these goals are simply targets the regulators are striving to. Our FDA normally shoots for 6 months in setting their PDUFA date for anything worthy of priority review, and that certainly includes all deadly diseases, like cancer. All the regulators can delay without denying, but I believe we're in a good position to get the UK decision on time, or early.
I forget who appeared to have relationships with the UK regulators, but I believed the indication that now RFI was generated in the initial review period, so I believe that we're on track for a very rapid approval.
The only approvals I've been involved with never had the sponsor say anything about discussions with the regulator from the time they filed until they received something official from the regulator. If it wasn't an approval, they announced what was being required, in some cases it was data they could get that wouldn't cause a major delay, in others it was additional trials, and substantial delay. In every case that I believed a product should be approved, it was, but in some case it was after a multi-year delay for the new trials.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
